Summary
DexCom, Inc. (DXCM) filed an 8-K on January 15, 2010, to report on a material definitive agreement regarding a public offering of its common stock. The company entered into an Underwriting Agreement with Canaccord Adams Inc. for the sale of up to 4,025,000 shares of DexCom's common stock, including an overallotment option of 525,000 shares. The offering is priced to the underwriter at $8.30 per share and is being conducted under an existing shelf registration statement on Form S-3.
Key Highlights
- 1DexCom entered into an Underwriting Agreement with Canaccord Adams Inc. on January 14, 2010.
- 2The company plans to sell up to 4,025,000 shares of common stock.
- 3The offering includes an overallotment option for an additional 525,000 shares.
- 4The shares are being offered to the underwriter at a price of $8.30 per share.
- 5The offering is being conducted under DexCom's Form S-3 shelf registration statement.
- 6The expected closing date for the offering is January 21, 2010.
- 7The filing also includes supporting legal opinions and consents.
Frequently Asked Questions
The primary purpose of this 8-K filing is to announce and provide details about DexCom's entry into a material definitive agreement, specifically an Underwriting Agreement for a public offering of its common stock.
DexCom is offering up to 4,025,000 shares of its common stock. The price to the underwriter is $8.30 per share, which includes shares sold under an overallotment option.
The offering is expected to close on January 21, 2010.
Canaccord Adams Inc. is acting as the Underwriter for this offering, purchasing the shares from DexCom and presumably reselling them to the public.